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A b s t r A c t
Recently, the term monoclonal gammopathy of renal significance (MGRS) was used 
to describe monoclonal gammopathies capable of causing kidney damage resulting in 
chronic kidney impairement and end-stage renal disease. By definition, patients with 
MGRS have small plasma-cell or B-cell clones that do not meet the criteria for mul-
tiple myeloma or lymphoma, and are frequently mistaken as monoclonal gammopa-
thies of undetermined significance (MGUS). As treatment is not recommended for 
MGUS, appropriate therapy is commonly withheld. Therefore, a high index of clinical 
suspicion for MGRS and a multidisciplinary approach are essential to avoid delayed 
diagnosis and the development of MGRS-related end-stage renal disease.
I N t r O D U c t I O N
There are several possible mechanisms by which a plasma-cell clone may cause 
renal impairment. The prototype renal disorder associated with a plasma-cell neoplasm 
is myeloma cast nephropathy in which a high disease burden leads to overproduction 
of light chains and formation of casts that obstruct renal tubules.1,2
Unlike multiple myeloma (ΜΜ), there are several other ways by which a mono-
clonal gammopathy produced even from a small plasma-cell clone may lead to renal 
impairment. In these cases, the production of nephrotoxic monoclonal proteins is 
responsile for the renal damage. From a hematological perspective, such cases may 
be mistakenly diagnosed as monoclonal gammopathy of undetermined significance 
(MGUS).3 Therefore, the term “monoclonal gammopathy of renal significance” 
(MGRS) was introduced in 2012 by the International Kidney and Monoclonal Gam-
mopathy Research Group to differentiate MGUS from monoclonal gammopathies 
associated with renal dysfunction. The group of MGRS is heterogenous, including 
several different histological entities.4
Our aim in this article is to provide a contemporary summary of the classification 
of MGRS and discuss various diagnostic challenges faced by clinicians when consulting 
patients with suspected MGRS.
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t y P e s  O F  P L A s M A - c e L L  D I s O r D e r s
Knowledge of the different types of plasma-cell disorders is 
central to understanding the concept of MGRS. We will start 
this article with a brief description of the classification criteria 
for the various types of plasma-cell disorders. 
Monoclonal plasma-cell disorders include MGUS, smold-
ering myeloma (SMM), and ΜΜ. These disorders are differen-
tiated on the basis of well-defined criteria. MM is characterized 
by ≥10% clonal bone-marrow plasma cells and evidence of 
end-organ damage — i.e., hypercalcemia, renal insufficiency, 
anemia, and lytic bone lesions (CRAB criteria). In 2014, the 
diagnostic criteria were updated by adding biomarkers that 
can identify patients who will develop end-organ damage. 
These criteria, so-called “myeloma defining events” (MDE), 
include ≥60% clonal bone-marrow plasma cells, involved-to-
uninvolved free-light-chain ratio ≥100, and ≥2 focal lesions 
(≥5 mm) on MRI.5
Smoldering multiple myeloma (SMM) is defined by a se-
rum monoclonal protein ≥30 g/l, clonal bone-marrow plasma 
cells ≥10%, and absence of CRAB/MDE. MGUS is defined 
by serum paraprotein <30 g/l, bone-marrow plasma cells 
<10%, and absence of CRAB. MGUS is common in people 
over 50 years with an incidence of 3.5% and 5% for those 
over 70 years.6
The hematological features of MGRS are frequently com-
patible with MGUS. By contrast to MGUS, MGRS are rare 
conditions. In MGRS, a monoclonal protein produced from a 
plasma-cell clone is directly linked to renal damage.
w H e N  s H O U L D  M G r s  b e  s U s P e c t e D ?
A high index of suspicion for MGRS should be maintained 
in patients with renal impairment in whom a monoclonal 
paraprotein is found in serum or urine or have evidence 
of a monoclonal plasma-cell disorder in the bone marrow. 
Diagnosis of MGRS relies on renal histology to demonstrate 
pathological evidence of paraprotein-induced renal damage 
and exclude cast nephropathy as well as other causes of renal 
disease such as diabetes and hypertension. As seen in the fol-
lowing examples, patients can present to either a nephrologist 
or hematologist.
c A s e  1
A 68-year-old man was admitted to our Nephrology De-
partment with proteinuria and deterioration of renal function 
(creatinine 1.8 mg/dl) on routine annual tests. His history 
was unremarkable except for mild hypertension treated with 
amlodipine. He had not taken nephrotoxic drugs. Renal ultra-
sound showed no abnormalities. Further evaluation showed 
mild normocytic anemia, 24-hour urine protein 1.7 g, and 
ANA 1:160 with normal C3, C4, and RF. Hepatitis B and C 
were negative. Serum protein electrophoresis was negative 
with normal immunoglobulin levels. Urine electrophoresis 
was negative, however, urine immunofixation revealed a 
small kappa-free monoclonal component. MGRS was sus-
pected and kidney biopsy showed findings consistent with 
light-chain deposition disease. On hematological evaluation, 
bone-marrow biopsy showed 5% kappa-restricted monoclonal 
plasma cells consistent with MGUS. The patient was treated 
with chemotherapy with improvement in renal parameters.
c A s e  2
A 60-year-old woman with a history of IgG kappa MGUS 
was examined during a routine follow-up. She reported having 
elevated blood pressure and discoloration of her fingers after 
exposure to cold in the last month. There was no change in 
the paraprotein level, as compared to previous examinations. 
Urinalysis showed protein 1+, 10-12 erythrocytes/hpf, and oc-
casional casts. Laboratory tests revealed creatinine 2.1 mg/dl 
and mild proteinuria (400 mg/24h). She was referred to a neph-
rologist. Testing for ANA, C3, C4, RF, hepatitis B and C was 
negative. Kidney biopsy showed evidence of cryoglobulinemic 
glomerulonephritis with monoclonal kappa light-chain stain-
ing. Trace cryoglobulin was found in serum (cryocrit <0.5%). 
The patient was referred to the Hematology Department for 
management of type I cryoglobulinemia.
D I A G N O s t I c  A P P r O A c H  
I N  s U s P e c t e D  M G r s
H e M A t O L O G I c A L  e vA L U A t I O N
Hematological evaluation includes serum and urine pro-
tein electrophoresis combined with immunofixation (IFX) and 
serum free light-chain (FLC) analysis. 
Serum protein electrophoresis (SPEP) can detect a para-
protein when its concentration is ≥0.5 g/l. IFX is more sensi-
tive, able to detect monoclonal proteins ≥0.15 g/l. Knowing 
these limitations is important because the concentration of 
monoclonal protein in some cases of MGRS may be below 
threshold.7 Plasma cells may produce intact immunoglobulin 
or light chain alone. Light chains are rapidly excreted and 
concentrated in urine, therefore, serum electrophoretic assays 
often fail to identify monoclonal light chains. Urine protein 
electrophoresis and immunofixation from a 24-hour urine 
collection can detect urinary light chains at a concentration of 
>0.01 mg/l.7 The serum free light-chain (FLC) assay measures 
free-kappa and free-lambda light chain with increased sensitiv-
ity using a nephelometric immunoassay. The normal range of 
the free kappa-to-lambda ratio is 0.26-1.65 with normal renal 
function, and 0.37-3.17 in renal impairment.8
Bone-marrow aspiration and biopsy with immunohisto-
chemical analysis should be performed in suspected MGRS 
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to evaluate the underlying plasma-cell dyscrasia (or B-cell 
clone). Usually, bone marrow aspiration and trephine biopsy 
are reported to show only a small increase in the percentage 
of plasma cells or to be normal. Flow cytometry should be 
undertaken to establish clonality whenever small numbers 
of plasma cells are present as monoclonal plasma cells are 
detectable in 97% of patients by immunophenotyping. Bone-
marrow cytogenetics and fluorescent in situ hybridization 
(FISH) analysis may provide useful additional information.9, 10
N e P H r O L O G I c A L  e vA L U A t I O N
Patients may present with diverse clinical manifestations 
depending on the underlying renal lesions such as acute kid-
ney injury (AKI), selective or non-selective proteinuria, acute 
glomerulonephritis/nephritic syndrome, Fanconi’s syndrome, 
and microscopic hematuria, reflecting the heterogeneity of the 
pathologic features in patients with MGRS. The type of renal 
injury depends on the molecular and physicochemical proper-
ties of the monoclonal protein and not its “burden” as in cast 
nephropathy. Kidney biopsy is indicated in all patients with 
suspected MGRS to assess the type of renal injury, severity of 
renal damage, impact on renal function, generation of fibrous 
tissue, and renal prognosis. Specimens should be examined 
with light microscopy (LM), immunohistochemistry (IHC), 
immunofluorescence (IF), and electron microscopy (EM). 
Importantly, since diagnosis is often based on subtle mor-
phological changes, evaluation by an expert renal pathologist 
should be sought for a definite diagnosis. 
c L A s s I F I c A t I O N  O F  M G r s
MGRS are classified anatomically, taking into account the 
position of the primary renal lesion caused by the deposition 
of the monoclonal protein and its clinical sequelae (Table 1). 
However, LM and IF are not always capable to determine the 
nature of the monoclonal deposits. EM is particularly valuable 
for this purpose, and a more accurate classification of MGRS 
is based on the ultrastructural appearance and pattern of the 
monoclonal immunoglobulin deposits (organized deposits 
versus non-organized deposits) (Fig. 1). Organized deposits 
occur extracellularly in various forms (fibrils, microtubules, 
Table 1. Primary renal lesions and clinical manifestations.
DISeaSe Glomerulus Tubular Proteinuria GFR  Hematuria
AL Amyloidosis  ++ + ++ +  ±
Cryoglobulinemic GN  ++ - + +  +
Fibrillary GN  ++ + ++ +  +
LCDD  ++ ++ + ++  +
C3 GN  ++ - ++ +  +
PGNMID  ++ - ++ +  +
GN: denotes glomerulonephritis; LCDD: denotes light-chain deposition disease; PGNMID: denotes proliferative glomerulonephritis with mono-
clonal IgG deposits.
FIGUre 1. Diagram of MGRS based on the deposits. GN: denotes glomerulonephritis; LCDD: denotes light-chain deposition disease; 
PGNMID: denotes proliferative glomerulonephritis with monoclonal IgG deposits.
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curved microtubules, crystals and fingerprints), diameters, and 
localizations. Non-organized deposits usually have a micro-
granular appearance which is also seen with IF microscope.11
M G r s  w I t H  O r G A N I Z e D  D e P O s I t s
1 .  I M M U N O G L O b U L I N  L I G H t- c H A I N  ( A L)  
A N D  H e Av y- c H A I N  ( A H )  A M y L O I D O s I s
Amyloidosis is a general term for diseases of protein 
folding in which a precursor protein aggregates and forms 
insoluble amyloid fibrils deposited extracellularly in tissues.12, 
13 Monoclonal immunoglobulin light chain and heavy chain 
are responsible for AL and AH amyloidosis, respectively. AH 
amyloidosis is extremely rare. In AL amyloidosis, the fibrils 
are formed by a fragment of a monoclonal light chain; lambda 
light chains are more commonly associated with amyloid than 
kappa in approximately a 3:1 ratio. Typically, the amyloidog-
enic clone is small (bone-marrow plasma-cell count 5-10%).14 
Kidney, heart, liver, and peripheral nerves may be affected. 
60% of patients are between 50 and 70 years old at diagnosis 
and only 10% are aged under 50 years. 
Using LM, renal amyloid appears as amorphous material 
occurring mainly in the mesangium and basement membranes 
of the glomerulus. Amyloid may also be found in the tubuloint-
erstitium and in the vessel walls. Characteristically, the lesions 
stain positive with Congo red, producing a classical apple green 
birefringence under polarized light (Fig. 2). Silver stains are 
negative and PAS stain is usually weakly positive. IF reveals 
a single light-chain isotype, usually lambda. On EM, amyloid 
contains randomly arrayed fibrils 8-15 nm in diameter.15,16
From a clinical perspective, AL amyloidosis is a disease 
with insidious onset. Although AL amyloid deposits generally 
affect multiple organs, dysfunction of one particular organ 
often predominates. Nearly one half of patients have dominant 
renal amyloid at diagnosis which is predominantly a glomeru-
lar lesion characterized by substantial proteinuria (>0.5 g/24 
hours). Albumin is the main urinary protein consistent with 
glomerular involvement ranging from subnephrotic to ne-
phrotic, frequently accompanied by other symptoms and signs 
of the nephrotic syndrome. Symptoms include ankle swelling, 
fatigue, loss of energy, peripheral edema, pleural effusions, and 
occult pericardial effusions. Loss of renal excretory function is 
common in AL amyloidosis although presentation with pro-
gressive renal failure at diagnosis is rare. Extensive deposits in 
the interstitium and vessels are characteristically accompanied 
by a decline in GFR. Less common features include arterial 
hypertension, nephrogenic diabetes insipidus, and Fanconi’s 
syndrome owing to amyloid deposits in the vasculature, col-
lecting duct, and proximal tubules, respectively. Notably, there 
is poor correlation between the extent of amyloid deposits and 
severity of clinical findings.15,17,18
2 .  c r y O G L O b U L I N e M I c  G L O M e r U L O N e P H r I t I s
Cryoglobulins are serum immunoglobulins that precipitate 
below 37oC and dissolve upon rewarming. Cryoglobulinemia 
has been described in various illnesses, including hepatitis C, 
lymphoproliferative disorders, systemic lupus erythematosus, 
FIGUre 2. Renal AL amyloidosis. Congo red stain showing amyloid deposits in mesangium, vessels and tubules (arrows in left 
panel), that demonstrate typical apple green birefringence with polarized light (right panel). (from K. Liapis: personal archive).
REDUCING DIAGNOSTIC ERRORS — RECOGNIzING MGRS
7
and Sjögren’s syndrome.19 Cryoglobulinemia is classified on 
the basis of the clonality and type of immunoglobulin. Type 
I cryoglobulinemia consists of monoclonal immunoglobulin 
(IgM, IgG, or IgA) cryoglobulins. Type II cryoglobulinemia 
consists of a mixture of monoclonal IgM and polyclonal IgG 
cryoglobulins. Type III cryoglobulinemia consists of a mixture 
of two or more immunoglobulin isotypes without a mono-
clonal component. Cryglobulin types I and II may be seen in 
association with a monoclonal plasma-cell or B-cell disorder.9 
Cryoglobulinemia is complicated by cryoglobulinemic glo-
merulonephritis (membranoproliferative glomerulonephritis) 
in 25%, which may present with the clinical picture of nephritic 
syndrome, nephrotic syndrome, hypertension, subnephrotic 
proteinuria, hematuria, and AKI.20,21
Using LM, cryoglobulinemic glomerulonephritis shows 
features of membranoproliferative or proliferative glomeru-
lonephritis with hyaline thrombi within capillaries (Fig. 3). 
Silver staining shows segmental duplication of capillary walls 
and mesangial expansion and proliferation. IF shows staining 
of capillary thrombi that are monoclonal for light chain (more 
frequently kappa than lambda kappa in approximately a 3:1 ra-
tio). When viewed with EM, cryoglobulin deposits are found in 
the glomeruli, mainly in the subendothelial wall and inside the 
capillary lumen leading to capillary obstruction. Specific ap-
pearances of the subendothelial deposits have been described 
including fibrillar, microtubular, and fingerprint forms.16,20
3 .  F I b r I L L A r y  G L O M e r U L O N e P H r I t I s  ( F G )
FG is a rare disorder, seen in less than 1% of renal biopsy 
specimens.22 Clinically, patients may present with various 
degrees of renal insufficiency, nephrotic-range proteinuria, 
hypertension, and microhematuria.23,24 FG is a difficult di-
agnosis that requires considerable expertise and use of EM. 
Histologically, it is characterized by mesangial hypercellular-
ity, duplication of the glomerular basement membranes, and 
glomerular deposits of Congo-red negative fibrillary material. 
These fibrils usually stain with IgG and C3 immunostains. By 
contrast to amyloid fibrils, FG shows randomly arranged fibrils 
that are 16 to 24 nm in diameter (Fig. 4).24,25 Only a minority 
of FG cases are associated with monotypic glomerular depos-
its, as seen on IF and IHC studies, and therefore, should be 
considered consistent with MGRS.16
4 .  I M M U NO tAc t OI D G L OM e rU L ON e P H r I t I s  ( IG)
IG is an uncommon entity characterized by microtubular 
monoclonal immunoglobulin deposits in the glomeruli. To 
make a diagnosis, cryoglobulinemic glomerulonephritis and lu-
pus nephritis should be ruled out.26 LM findings in cases of IG 
are non-specific, including Congo-red negative and silver-stain 
negative mesangial deposits of amorphous material accompa-
nied by membranous or membranoproliferative pattern. There 
are no lesions in the tubules, interstitium, or blood vessels. 
The deposits stain with anti-IgG and anti-C3 and may exhibit 
light-chain restriction. The EM picture is pathognomonic: IG 
deposits consist of thick microtubules (rather than fibrils) 30-
50 nm arranged in parallel arrays.27-29 Clinical features include 
hematuria (70%), nephrotic proteinuria (70%), hypertension 
(65%), and end-stage renal disease (40-50%).29
IG should be differentiated from FG – both conditions con-
tain non-amyloid (Congo-red negative), organized glomerular 
immune deposits. Although distinct definitions based on the 
FIGUre 3. Cryoglobulinemic glomerulonephritis. Hematoxylin 
and eosin stain showing membranoproliferative glomerulone-
phritis with intracapillary hyaline thrombi (arrow). (Department 
of Histopathology, National and Kapodistrian University of 
Athens).
FIGUre 4. Electron microscopy in fibrillary glomerulonephritis 
(FG) showing randomly arranged fibrils. (Department of His-
topathology, National and Kapodistrian University of Athens).
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fibril morphology have been described, there is a considerable 
overlap between these 2 entities. For diagnosis of FG and IG, 
examination with EM is needed. As mentioned above, only a 
few cases demonstrating monotypic glomerular deposits on IF 
analysis should be considered to represent MGRS and, thus, 
warrant further investigation and referral to a hematologist. 
M G r s  w I t H  N O N - O r G A N I Z e D 
D e P O s I t s
1 .  M O N O c L O N A L  I M M U N O G L O b U L I N 
D e P O s I t I O N  D I s e A s e  ( M I D D )
MIDD includes 3 rare conditions associated with the 
production and deposition of different monoclonal proteins: 
light-chain deposition disease (LCDD), heavy-chain deposi-
tion disease (HCDD) and light-chain and heavy-chain deposi-
tion disease (LHCDD).30 The pattern of deposition, clinical 
features and prognosis are similar between LCDD, HCDD 
and LHCDD.31 LCDD (also called Randall disease) is the 
most common type of MIDD, usually involving the kappa light 
chain. Notably, LCDD is associated with MM in 65%.32 In 
addition, LCDD is found in 5% of patients with MM.30 Renal 
involvement is almost always present in LCDD resulting in 
proteinuria, renal impairment, and microscopic hematuria. In 
contrast to AL amyloidosis, MIDD is characterized by early, 
progressive decline in renal function. Extrarenal manifesta-
tions include heart, liver, nerves, spleen, gastrointestinal tract 
and skin involvement.30 LCDD has a mean overall survival of 
49 months similar to AL amyloidosis.33 Key diagnostic features 
in LCDD include thickening of tubular basement membranes, 
nodular glomerulosclerosis, and expansion of the mesangial 
matrix due to deposition of amorphous Congo-red negative 
material.30 There is light-chain restriction as seen with use of 
anti-kappa or anti-lambda stains. In HDCC, the glomerular 
deposits consist of γ, α, or μ heavy-chain, whereas light chain 
IF is negative and on EM, granular, electron-dense deposits 
are observed in the glomeruli and tubular basement mem-
branes.34,35
2 .  c 3  G L O M e r U L O PA t H y  
( c 3  G L O M e r U L O N e P H r I t I s  
A N D  D e N s e  D e P O s I t  D I s e A s e )
C3 glomerulopathy includes C3 glomerulonephritis and 
dense deposit disease (DDD). The activation of the alternative 
pathway of the complement resulting in glomerular aggrega-
tion plays a key role in the pathophysiology of C3 glomeru-
lopathy.36 Some cases of C3 glomerulopathy are associated 
with the presence of a monoclonal paraprotein in serum and 
MGUS in the bone marrow. Such cases are thought to rep-
resent MGRS, on the basis of laboratory evidence suggesting 
a causal relationship between a monoclonal immunoglobulin 
and complement activation.37 The mechanism by which C3 
deposition occurs is not fully understood, however, it has 
been suggested that the monoclonal immunoglobulin may 
bind to and inactivate factor H of the complement cascade.38 
The characteristic finding in DDD and C3 glomerulonephritis 
is a membranoproliferative glomerulonephritis. Mesangial, 
subendothelial and intracapillary proliferation is common. 
Staining for C3 is seen in the mesangial and capillary loops 
but staining for monoclonal immunoglobulins is negative. 
EM demonstrates a distinctive appearance of “sausage-like” 
intramembranous deposits in DDD. C3 glomerulonephritis 
contains less distinctive subendothelial, intramembranous, 
and subepithelial C3 deposits.16,36 Proteinuria, hematuria, and 
renal insufficiency may be present.39
3 .  P r O L I F e r A t I v e  G L O M e r U L O N e P H r I t I s 
w I t H  M O N O c L O N A L  I G G  D e P O s I t s  ( P G N M I D )
In PGNMID, a monoclonal immunoglobulin is deposited 
in the mesangium and along the capillary walls, leading to the 
activation of the classical pathway of the complement resulting 
in a capillary-wall remodelling and membranoproliferative 
glomerulonephritis.40 PGNMID differs from MIDD because 
PGNMID is limited in the glomeruli whereas MIDD affects 
glomeruli as well as tubules. PGNMID has a monoclonal stain-
ing pattern whereas other, more common, membranoprolif-
erative glomerulonephritides contain polyclonal depositions. 
The characteristic finding in renal biopsy is a membranopro-
liferative glomerulonephritis with monoclonal staining for a 
single light chain and a single heavy chain. The monoclonal 
immunoglobulin is usually IgG although IgA PGNMID has 
also been reported.9,41 EM reveals mesangial and subendothe-
lial non-fibrilar electron-dense deposits.42 PGNMID should 
be differentiated from cryoglobulinemic glomerulonephritis. 
Notably, in the majority of patients, the concentration of the 
monoclonal immunoglobulin is very low in serum so that it is 
undetectable even on IFX study and a high index of suspicion 
is required for diagnosis.40 Bone-marrow examination includ-
ing flow cytometry immunophenotyping usually reveals the 
underlying plasma-cell clone.
c O N c L U s I O N
Diagnosis of MGRS requires multidisciplinary input from 
hematologists, nephrologists, and pathologists. Although rare, 
a high index of suspicion should be maintained for MGRS. 
Therefore, all patients with MGUS should have periodic tests 
of renal function including urinalysis for proteinuria and hema-
turia, and hematologists should be alert to early detect any sign 
of possible renal damage and organize a referral to the renal 
team. A renal biopsy must always be performed when MGRS 
is suspected. Recognition of MGRS is important because renal 
function may improve significantly with appropriate treat-
ment. Although a description of the therapeutic approaches 
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is not the purpose of this article, it should be mentioned that 
patients should be treated with chemotherapy targeting the 
responsible clone, similar to patients with myeloma cast ne-
phropathy. Preservation and restoration of kidney function 
are possible with successful chemotherapy. In addition to 
end-stage renal disease, the persistence of the monoclonal 
gammopathy is associated with high rates of recurrence after 
kidney transplantation; however, achievement of hematologic 
response with use of appropriated therapy is able to prevent 
recurrence after kidney transplantation.
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